Skip to main content

Aggressive, Early Disease-Modifying Therapy May Slow MS Progression

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 27, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Sept. 27, 2024 -- Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of the American Neurological Association, held Sept. 14 to 17 in Orlando, Florida.

Jack Reeves, Ph.D., from State University of New York at Buffalo, and colleagues assessed the relationship between new PRL appearance, disappearance, or persistence over five years and the prevalence of confirmed disability progression (CDP) and progression independent of relapse activity (PIRA). The analysis included 93 people with MS who had 3T magnetic resonance imaging at baseline.

The researchers found that significantly increased odds of CDP were associated with the number of persisting PRLs (exp(β) = 1.24). There was also a significant association between increased odds of PIRA occurrence and number of persisting PRLs (exp(β) = 1.35) and the presence of newly appearing PRLs (exp(β) = 8.68). Reducing the number of persisting PRLs to zero in people with MS and at least one baseline PRL (PRL+) would result in an estimated 45.6 percent relative reduction in five-year PIRA prevalence (26.1 to 14.2 percent of PRL+) and a 27.1 percent relative reduction in five-year CDP prevalence (30.4 to 22.2 percent of PRL+). Completely preventing new PRLs in the whole cohort would result in an estimated 14.0 percent relative reduction in five-year PIRA prevalence (22.9 to 19.7 percent).

"Our data suggest that development of novel disease-modifying therapies that efficaciously target ongoing chronic active inflammation would significantly reduce the burden of clinical disease progression in the MS population," the authors write.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics

WEDNESDAY, May 21, 2025 -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by...

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

TUESDAY, May 20, 2025 -- Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a...

CVD Mortality Higher in Women Than Men With Immune-Mediated Inflammatory Diseases

TUESDAY, May 13, 2025 -- For patients with immune-mediated inflammatory diseases (IMID), cardiovascular disease (CVD) mortality decreased from 1999 to 2020, but sex disparities...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.